BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Inc. (BLFS) – Form 4 insider transaction
Chief Human Resources Officer Sarah Aebersold reported the sale of 711 shares of common stock on 16 June 2025 at a price of $22.23 per share. The transaction was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective 11 December 2024, indicating the sale was scheduled in advance and not triggered by undisclosed information.
Following the sale, Aebersold’s direct ownership stands at 78,721 shares. Calculations from the disclosed data show the disposal represents roughly 0.9 % of her prior position (79,432 shares), suggesting only a modest reduction in personal exposure to the company’s equity.
No derivative securities were bought or sold and no additional transactions were reported. The filing contains no information about company operations, earnings, or strategic initiatives; it purely documents a routine insider trade.